Andisheh-Tadbir A, Gorgizadeh A. CD166 expression
in dentigerous cyst, keratocystic
odontogenic tumor and ameloblastoma.
J Clin Exp Dent. 2016;8(3):e236-40.
doi:10.4317/jced.52381
References
|
1.
Alves Pereira KM, do Amaral BA, dos Santos BR, Galvăo
HC, FreitasRde A, de Souza LB. Immunohistochemical expression of E-cadherin and beta-catenin in ameloblastomas and
tooth germs. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:425-31. |
|
|
|
|
|
2. Ofori-Acquah
SF, King JA. Activated leukocyte cell adhesion molecule: a new paradox in cancer.Transl Res. 2008;151:122-8. |
|
|
|
|
|
3. Tuyns
AJ, Estčve J, Raymond L, Berrino
F, Benhamou E, Blanchet F, et al. Cancer of the
larynx/hypopharynx, tobacco and alcohol: IARC
international case-control study in Turin and Varese (Italy), Zaragoza and
Navarra (Spain), Geneva (Switzerland) and Calvados (France). Int J Cancer. 1988;41:483-91. |
|
|
|
|
|
4. Weidle
UH, Eggle D, Klostermann
S, Swart GW. ALCAM/CD166: cancer-related issues. Cancer Genomics Proteomics. 2010;7:231-43. |
|
|
|
|
|
5.
van Kilsdonk JW, Wilting
RH, Bergers M, van Muijen
GN, Schalkwijk J, van Kempen
LC, et al. Attenuation of melanoma invasion by a secreted
variant of activated leukocyte cell adhesion molecule. Cancer Res. 2008;68:3671-9. |
|
|
|
|
|
6. Dalerba
P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, et al.
Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci
U S A. 2007;104:10158-63. |
|
|
|
|
|
7. Kristiansen G, Pilarsky C, Wissmann C, Stephan
C, Weissbach L, Loy V, et al. ALCAM/CD166 is
up-regulated in low-gradeprostate cancer and
progressively lost in high-grade lesions.Prostate. 2003 ;54:34-43. |
|
|
|
|
|
8. Kristiansen G, Pilarsky C, Wissmann C, Kaiser
S, Bruemmendorf T, Roepcke
S, et al. Expression profiling of microdissected
matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic
markers for patient survival. J Pathol. 2005;
205:359-76. |
|
|
|
|
|
9. Weichert
W, Knösel T, Bellach J, Dietel M, Kristiansen G. ALCAM/CD166
is overexpressed in colorectal carcinoma and
correlates with shortened patient survival. J Clin Pathol. 2004;57:1160-4. PMid:15509676 |
|
|
|
|
|
10. King JA, Ofori-Acquah SF, Stevens T, Al-Mehdi
AB, Fodstad O, Jiang WG. Activated leukocyte cell
adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res.
2004;6:R478-87. |
|
|
|
|
|
11. Yan M, Yang X, Wang L,
Clark D, Zuo H, Ye D, et al. Plasma membrane
proteomics of tumor spheres identify CD166 as a novel marker for cancer
stem-like cells in head and neck squamous cell
carcinoma. Mol Cell Proteomics. 2013;12:3271-84. |
|
|
|
|
|
12. Goloudina
AR, Demidov ON, Garrido
C. Inhibition of HSP70: a challenging anti-cancer strategy. Cancer Lett. 2012;325:117-24. |
|
|
|
|
|
13. de Vicente J-C, Torre-Iturraspe A, Gutiérrez A-M, Lequerica-Fernández P. Immunohistochemical
comparative study of the odontogenic keratocysts and other odontogenic
lesions. Med Oral Patol Oral Cir
Bucal. 2010;15:e709-15. |
|
|
|
|
|
14.
de Andrade Santos PP, de Aquino ARL, Oliveira
Barreto A, de Almeida Freitas R, Galvăo HC, de
Souza LB. Immunohistochemical expression of nuclear factor κB, matrix metalloproteinase 9, and endoglin (CD105) in odontogenickeratocysts,
dentigerous cysts, and radicular
cysts. Oral Surg Oral Med Oral Pathol
Oral Radiol Endod. 2011;112:476-83. |
|
|
|
|
|
15. Hakim SG, Kosmehl H, Sieg P, Trenkle T, Jacobsen HC, Attila Benedek
G, et al. Altered expression of cell-cell adhesion molecules β-catenin/E-cadherin and related Wnt-signaling
pathway in sporadic and syndromal keratocystic odontogenic tumors.
Clin Oral Investig. 2011;15:321-8. |
|
|
|
|
|
16. Kubota Y, Ninomiya T, Oka S, Takenoshita
Y, Shirasuna K. Interleukin-1alpha-dependent
regulation of matrix metalloproteinase-9(MMP-9) secretion and activation in
the epithelial cells of odontogenic jaw cysts. J Dent Res. 2000;79:1423-30. |
|
|
|
|
|
17. Gosau
M, Draenert FG, Müller S,
Frerich B, Bürgers R,
Reichert TE, et al. Two modifications in the treatment of keratocystic
odontogenic tumors (KCOT) and the use of Carnoy's solution (CS)-a retrospective study lasting
between 2 and 10 years. Clin Oral Investig. 2010;14:27-34. |
|
|
|
|
|
18. Henriques
Á, Vasconcelos MG, Galvăo
HC, de Souza LB, de Almeida Freitas R. Comparative
analysis of the immunohistochemical expression of
collagen IV, MMP-9, and TIMP-2 in odontogenic cysts
and tumors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;11:68-75. PMid:21911204 |
|
|
|
|
|
19. Wang J, Zhong M, Zhang LZ, Wang Y, Wang ZY .
Expression of ICAM-1 and VCAM-1 in human ameloblastoma
and odontogenic keratocyst.
Shanghai Kou Qiang Yi Xue.
2003;12:273-6. PMid:14966640 |
|
|
|
|
|
20.
Salehinejad J, Saghafi S,
Sharifi N, Zare-Mahmoodabadi
R, Saghravanian N, Ghazi
N, et al. Evaluation of osteopontin
and CD44v6 expression in odontogenic cystic lesions
by immunohistochemistry. Pathol
Res Pract. 2012;208:410-4. |
|
|
|
|
|
21. Maree
M, Leroy A. Clinical, cellular and molecular aspects of cancer invasion. Physiol Rev. 2003;83:337-76. |
|
|
|
|
|
22. Hanahan
D, Weinberg RA.The hallmarks of cancer. Cell. 2000;100:57-70. PMid:10647931 |
|
|
|
|
|
23. Kumamoto H. Molecular
pathology of odontogenic tumors. J Oral Pathol Med. 2006;35:65-74. |
|
|
|
|
|
24.
Rosso O, Piazza T, Bongarzone
I, Rossello A, Mezzanzanica
D, Canevari S, et al. The ALCAM shedding by the metalloprotease
ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res. 2007;5:1246-53. |
|
|
|
|
|
25. Gardner DG, Heikinheimo K, Shear M, Philipson
HP, Coleman H. Ameloblastomas. In: World Health
Organization Classification of Tumours.Pathology
and Genetics of Head and Neck Tumours. BarnesL, EvesonJW, ReichartP, Sidransky D (eds.). IRACPress, Lyon pp296-300, 2005. |
|
|
|
|
|
26. Hansen AG, Arnold SA,
Jiang M, Palmer TD, Ketova T, Merkel A, et al.
ALCAM/CD166 is a TGF-β-responsive marker and functional regulator of
prostate cancer metastasis to bone. Cancer Res. 2014;74:1404-15. |
|
|
|
|
|
27. Kaur
J, Sawhney M, DattaGupta
S, Shukla NK, Srivastava
A, Walfish PG, et al. Clinical significance of
altered expression of β-catenin and E-cadherin in oral dysplasia and cancer: potential link
with ALCAM expression. PLoS One. 2013;8:e67361 |
|
|
|
|
|
28.
González-Alva P, Tanaka
A, Oku Y, Miyazaki Y, Okamoto
E, Fujinami M,et
al. Enhanced expression of podoplanin
in ameloblastomas. J Oral Pathol
Med. 2010;39:103-9. |
|
|
|
|
|
29.
Shimada Y, Katsube K, Kabasawa Y, Morita K, Omura K,
Yamaguchi A, et al. Integrated
genotypic analysis of hedgehog-related genes identifies subgroups of keratocystic odontogenic tumor
with distinct clinicopathological features. PLoS One. 2013;8:e70995. |
|
|
|
|
|
30. van den Brand M, Takes
RP, Blokpoel-deRuyter M, Slootweg
PJ, van Kempen LC. Activated leukocyte cell
adhesion molecule expression predicts lymph node metastasis in oral squamous cell carcinoma. Oral Oncol.
2010;46:393-8. |
|
|
|
|
|
31. Lunter
PC, van Kilsdonk JW, van Beek
H, Cornelissen IM, Bergers
M, Willems PH, et al. Activated leukocyte cell
adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth,
controls matrix metalloproteinase activity. Cancer Res. 2005;65:8801-8. |
|
|
|
|
|
32. Khalifa
GA, Shokier HM, Abo-Hager
EA. Evaluation of neoplastic nature of keratocystic odontogenic tumor
versus ameloblastoma. J Egypt Natl
Canc Inst. 2010;22:61-72. |
|
|
|
|